会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • C-kit ligand-based method for expanding peripheral blood cell levels
    • 用于扩增外周血细胞水平的基于C-kit配体的方法
    • US06403559B1
    • 2002-06-11
    • US09371261
    • 1999-08-10
    • Peter BesmerJochen BuckMalcolm A. S. MooreKarl Nocka
    • Peter BesmerJochen BuckMalcolm A. S. MooreKarl Nocka
    • A61K3804
    • A61K31/7072A61K38/00A61K38/193A61K38/202C07K14/475C07K14/52C07K14/705C07K14/71C07K14/715C07K16/22C12N15/87A61K2300/00
    • A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.
    • 提供了包含通过申请人纯化或由申请人的重组方法与其他造血因子组合产生的c-kit配体(KL)和药学上可接受的载体的药物组合物,以及治疗患者的方法,其包括向患者施用 本发明的药物组合物。 本发明提供了使用c-kit配体(KL)和纯化的c-kit配体(KL)多肽或其可溶性片段和其他造血因子的组合疗法。 它还提供单独使用KL或联合治疗的离体使用KL方法和组合物。 还描述了突变的KL拮抗剂。 这样的拮抗剂也可以是小分子。 还描述了作为治疗剂的KL的反义核酸。 最后,描述了利用KL在生殖细胞,肥大细胞和黑素细胞中的作用的组合物和方法。